All News

Progression of Undifferentiated Arthritis to Inflammatory Arthritis https://t.co/Ozr8jPnAcx https://t.co/Jctal4xznB

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

Which One is the Loneliest Number (9.27.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the regulatory approvals, announcements, guidelines and interesting journal articles from the past week on RheumNow.com. When not to use muscle relaxants, how frequent is loneliness in RA/PsA/SpA, and when to refer patients with Still's disease.

Read Article
Pain Relief with JAK Inhibitors or Anti-TNFs ? Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest. https://t.co/oIgNxBF518 https://t.co/L9g9MJQbQx

Links:

Dr. John Cush RheumNow ( View Tweet)
Stills,continuum

EULAR/PReS Still's Disease Management Recommendations

d Jack Cush, MD

Since 2022, EULAR and the Paediatric Rheumatology European Society (PReS) have been working to establish clinical practice guidelines for the diagnostics and management of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD). 

Read Article
hands.stiff2_.jpg

Pain Relief with JAK Inhibitors or Anti-TNFs ?

d MedPage Today

Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.

Read Article
ACR 2024 Abstracts are available. Let the fun begin..... https://t.co/uNLZBqjEX0 Search by term, title or abstract # here: https://t.co/Du1eN4gA9D or Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR 2024 Abstracts are available. Let the fun begin..... https://t.co/uNLZBqjEX0 Search by term, title or abstract # here: https://t.co/Du1eN4gA9D or Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR 2024 Abstracts are available. Let the fun begin..... https://t.co/uNLZBqjEX0 Search by term, title or abstract # here: https://t.co/Du1eN4gA9D or Search by sessions and topics here >> https://t.co/R7NH1jeHPj https://t.co/OCoTPr03nG

Links:

Dr. John Cush RheumNow ( View Tweet)
Danish cross-sectional survey 12 713 Inflam arthritis (RA, PsA, SpA) pts & found lonliness in one-third (RA 32%; 36% in PsA & SpA) and highest in SpA w/ depression (66%). Loneliness was correlated w/ disease activity. https://t.co/Q3IswbIwe6 https://t.co/GNohOkkmEw

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read overview of ILD & its Clinical Course inRheumatoid Arthritis. Metanalysis of 22 reports shows 6-19% of RA have ILD on HRCT. Article discusses early onset, progression and the monitoring and management of RA-ILD https://t.co/mqexPcruni https://t.co/One7XYn4wX

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of 5 Nordic registries & 29,478 RA & 10,919 PsA pts initiating 1st bDMARD,s (& 362,087 pop controls). Incident ILD was higher in RA (HR 9.7) & PsA (4.4). but MTX co-use (vs non-use) did not incr ILD in RA (HR 0.9; 0.7, 1.2) or PsA (HR 1.0) https://t.co/xY8COh85Bw https://t.co/weJGirfhDX

Links:

Dr. John Cush RheumNow ( View Tweet)
Treatment of Rheumatoid Arthritis (RA) associated Interstitial lung disease #ILD 2023 ACR/Chest Guideline #Rheumatology #MedTwitter https://t.co/hoW88BL2E2

Links:

Ask The Rheumatologist LastManStand85 ( View Tweet)
TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein… https://t.co/1NYgYtYKIr https://t.co/fMMy2DzSxN
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of JAKi in ILD (7 studies, 183 pts) showed increases in FVC (2 %), DLCO (3.1%) & improved Thoracic HRCT of 11%; only 5% had worsening of their ILD. Risk of ILD w/ JAKi was low ( 0.20/1000 PY) w rates similar to abatacept & rituximab https://t.co/UDJ1ZvtGhh https://t.co/WTQS67yDyl

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
Retrospective analysis of 63K Alopecia areata pts shows a higher risk of developing psychiatric (aHR 1.3) & autoimmune Dz (aHR 2.7), including SLE (aHR 5.7), atopic dermatitis (4.3), vitiligo (3.8), Sjogrens (3.7), Morphea (3.6), PsO (2.8), RA (1.8) https://t.co/gnEm9TsyoV https://t.co/XWA98sbRLp

Links:

Dr. John Cush RheumNow ( View Tweet)
IMPORTANT: Cost effectiveness analysis of the TREAT EARLIER RCT shows 88% probability that 1 yr of MTX in 236 pts w/ clinically suspect arthralgia was cost-effective. Results shows MTX Rx increased quality adjusted life years & reduced costs https://t.co/1BVxs77vo8 https://t.co/uQSQL5Eww9

Links:

Dr. John Cush RheumNow ( View Tweet)
early.RA_.jpg

TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients

d Jack Cush, MD

Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.

Read Article
Cancer presenting as Inflammatory low back pain? 34 Cases presenting as SpA over 10 yrs often w/ higher ESR/CRP/LDH levels. CA included myeloma, leukemia, lymphoma, CA of breast/lung/prostate & bone tumors. https://t.co/YYKYx39tbD https://t.co/m9uCbJBsnU

Links:

Dr. John Cush RheumNow ( View Tweet)
So You've Got RA and Want to Get Pregnant? Dr. David Liew reviews abstract POS0436 presented at Eular 2024 in Vienna, Austria. https://t.co/vG9l7kOReq https://t.co/xhumOCisOM

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.